PL3096798T3 - Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego - Google Patents
Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowegoInfo
- Publication number
- PL3096798T3 PL3096798T3 PL15740774T PL15740774T PL3096798T3 PL 3096798 T3 PL3096798 T3 PL 3096798T3 PL 15740774 T PL15740774 T PL 15740774T PL 15740774 T PL15740774 T PL 15740774T PL 3096798 T3 PL3096798 T3 PL 3096798T3
- Authority
- PL
- Poland
- Prior art keywords
- binding proteins
- plasma kallikrein
- hereditary angioedema
- kallikrein binding
- treating hereditary
- Prior art date
Links
- 206010019860 Hereditary angioedema Diseases 0.000 title 1
- 102000003827 Plasma Kallikrein Human genes 0.000 title 1
- 108090000113 Plasma Kallikrein Proteins 0.000 title 1
- 102000023732 binding proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/03—Phosphotransferases with a nitrogenous group as acceptor (2.7.3)
- C12Y207/03002—Creatine kinase (2.7.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21034—Plasma kallikrein (3.4.21.34)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461929716P | 2014-01-21 | 2014-01-21 | |
US201461944361P | 2014-02-25 | 2014-02-25 | |
US201462021397P | 2014-07-07 | 2014-07-07 | |
EP15740774.3A EP3096798B1 (en) | 2014-01-21 | 2015-01-21 | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
PCT/US2015/012212 WO2015112578A1 (en) | 2014-01-21 | 2015-01-21 | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3096798T3 true PL3096798T3 (pl) | 2021-07-26 |
Family
ID=53681890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL15740774T PL3096798T3 (pl) | 2014-01-21 | 2015-01-21 | Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego |
Country Status (18)
Country | Link |
---|---|
US (2) | US11084884B2 (pl) |
EP (2) | EP3096798B1 (pl) |
JP (3) | JP6845012B2 (pl) |
KR (4) | KR102424183B1 (pl) |
CN (2) | CN116585468A (pl) |
AU (3) | AU2015209481C1 (pl) |
BR (1) | BR112016016916B1 (pl) |
CA (1) | CA2937329C (pl) |
DK (1) | DK3096798T3 (pl) |
EA (1) | EA038532B1 (pl) |
ES (1) | ES2856076T3 (pl) |
IL (3) | IL246864B (pl) |
MX (2) | MX2016009428A (pl) |
NZ (2) | NZ761006A (pl) |
PL (1) | PL3096798T3 (pl) |
PT (1) | PT3096798T (pl) |
WO (1) | WO2015112578A1 (pl) |
ZA (2) | ZA201605342B (pl) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3459564B1 (en) | 2010-01-06 | 2021-10-27 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
KR102169651B1 (ko) | 2011-01-06 | 2020-10-23 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
US11156612B2 (en) | 2013-01-20 | 2021-10-26 | Takeda Pharmaceutical Company Limited | Methods of determining levels of cleaved and/or intact kininogen |
CN111704672B (zh) | 2013-03-15 | 2024-06-04 | 武田药品工业株式会社 | 抗血浆激肽释放酶抗体 |
JP6657098B2 (ja) | 2013-10-21 | 2020-03-04 | ダイアックス コーポレーション | 自己免疫疾患の診断と治療 |
ES2837858T3 (es) | 2013-10-21 | 2021-07-01 | Dyax Corp | Ensayos para determinar biomarcadores del sistema calicreína plasmática |
ES2856076T3 (es) | 2014-01-21 | 2021-09-27 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática y usos de las mismas en el tratamiento de angioedema hereditario |
IL247942B (en) | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
EP3916020A1 (en) * | 2015-03-30 | 2021-12-01 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
WO2017035263A1 (en) * | 2015-08-24 | 2017-03-02 | Biocryst Pharmaceuticals, Inc. | Compositions comprising a plasma kallikrein inhibitor |
PT3365685T (pt) * | 2015-10-19 | 2021-03-01 | Dyax Corp | Imunoensaio para detetar cininogénio de elevada massa molecular clivado |
IL311156A (en) | 2015-12-11 | 2024-04-01 | Takeda Pharmaceuticals Co | Plasma kallikrein inhibitors and their uses in the treatment of hereditary angioedema attack |
CN109716129B (zh) | 2016-09-16 | 2023-10-03 | 武田药品工业株式会社 | 用于遗传性血管性水肿的rna生物标记 |
MX2019002932A (es) * | 2016-09-16 | 2019-07-15 | Dyax Corp | Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto. |
KR20200067195A (ko) * | 2017-10-18 | 2020-06-11 | 리젠엑스바이오 인크. | 완전-인간 번역후 변형된 항체 치료제 |
AU2018374219C1 (en) | 2017-12-01 | 2023-05-11 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof |
CN110997917B (zh) | 2017-12-01 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
CN116375774A (zh) | 2017-12-29 | 2023-07-04 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
CN111655297A (zh) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
JP2022534069A (ja) * | 2019-05-24 | 2022-07-27 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体並びに調製方法と使用 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US5444156A (en) | 1985-07-12 | 1995-08-22 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human plasma prekallikrein |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
WO1987005396A1 (en) | 1986-03-03 | 1987-09-11 | Brigham And Women's Hospital | A method for evaluating nephrotoxicity |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5045452A (en) | 1988-09-02 | 1991-09-03 | Brigham And Women's Hospital | Method for evaluating nephrotoxicity |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
ATE275583T1 (de) | 1994-01-11 | 2004-09-15 | Dyax Corp | KALLIKREINHEMMENDE ßKUNITZ-DOMÄNEß-PROTEINE UND DERIVATEN DAVON |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
DE19632772A1 (de) | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Benzamidine |
NZ532896A (en) | 2001-11-08 | 2007-08-31 | Pdl Biopharma Inc | Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab |
EP2298278B1 (en) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prevention and reduction of blood loss and inflammatory response |
US20070253949A1 (en) | 2004-02-03 | 2007-11-01 | Stefan Golz | Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1) |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
HUE039108T2 (hu) | 2006-03-16 | 2018-12-28 | Dyax Corp | Készítmények és eljárások szembetegségek kezelésére |
CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
KR100846354B1 (ko) | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | 혈청 당단백질부터 분리한 폐암 진단용 마커 |
CA2693921A1 (en) * | 2007-07-20 | 2009-01-29 | Genesys Venture Inc. | Tissue kallikrein for the treatment of diseases associated with amyloid protein |
US20090105142A1 (en) | 2007-08-23 | 2009-04-23 | Genzyme Corporation | Treatment with kallikrein inhibitors |
WO2010080833A1 (en) * | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
CN101928346B (zh) | 2009-07-31 | 2013-01-16 | 华中科技大学同济医学院附属同济医院 | 一种抗人组织激肽释放酶单克隆抗体及其制备 |
EP3459564B1 (en) | 2010-01-06 | 2021-10-27 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
KR102169651B1 (ko) | 2011-01-06 | 2020-10-23 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
US8691861B2 (en) | 2011-04-13 | 2014-04-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
US11156612B2 (en) | 2013-01-20 | 2021-10-26 | Takeda Pharmaceutical Company Limited | Methods of determining levels of cleaved and/or intact kininogen |
RS58635B1 (sr) | 2013-01-20 | 2019-05-31 | Dyax Corp | Procena, testovi i lečenje pkal-posredovanih poremećaja |
CN111704672B (zh) | 2013-03-15 | 2024-06-04 | 武田药品工业株式会社 | 抗血浆激肽释放酶抗体 |
ES2856076T3 (es) * | 2014-01-21 | 2021-09-27 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática y usos de las mismas en el tratamiento de angioedema hereditario |
IL247942B (en) | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
EP3916020A1 (en) | 2015-03-30 | 2021-12-01 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
IL311156A (en) | 2015-12-11 | 2024-04-01 | Takeda Pharmaceuticals Co | Plasma kallikrein inhibitors and their uses in the treatment of hereditary angioedema attack |
CN109716137B (zh) * | 2016-09-16 | 2023-07-21 | 武田药品工业株式会社 | 用于与接触活化***相关的疾病的代谢产物生物标记 |
-
2015
- 2015-01-21 ES ES15740774T patent/ES2856076T3/es active Active
- 2015-01-21 NZ NZ761006A patent/NZ761006A/en unknown
- 2015-01-21 JP JP2016547570A patent/JP6845012B2/ja active Active
- 2015-01-21 KR KR1020167022785A patent/KR102424183B1/ko active IP Right Grant
- 2015-01-21 PT PT157407743T patent/PT3096798T/pt unknown
- 2015-01-21 KR KR1020247006911A patent/KR20240033156A/ko active Application Filing
- 2015-01-21 MX MX2016009428A patent/MX2016009428A/es unknown
- 2015-01-21 EP EP15740774.3A patent/EP3096798B1/en active Active
- 2015-01-21 AU AU2015209481A patent/AU2015209481C1/en active Active
- 2015-01-21 US US15/113,297 patent/US11084884B2/en active Active
- 2015-01-21 EP EP20209536.0A patent/EP3848057A1/en active Pending
- 2015-01-21 CA CA2937329A patent/CA2937329C/en active Active
- 2015-01-21 CN CN202310760869.5A patent/CN116585468A/zh active Pending
- 2015-01-21 BR BR112016016916-6A patent/BR112016016916B1/pt active IP Right Grant
- 2015-01-21 PL PL15740774T patent/PL3096798T3/pl unknown
- 2015-01-21 KR KR1020247010766A patent/KR20240049627A/ko active Search and Examination
- 2015-01-21 WO PCT/US2015/012212 patent/WO2015112578A1/en active Application Filing
- 2015-01-21 KR KR1020227025028A patent/KR20220107077A/ko not_active IP Right Cessation
- 2015-01-21 DK DK15740774.3T patent/DK3096798T3/da active
- 2015-01-21 CN CN201580010172.XA patent/CN106132442B/zh active Active
- 2015-01-21 NZ NZ723369A patent/NZ723369A/en unknown
- 2015-01-21 EA EA201691470A patent/EA038532B1/ru unknown
-
2016
- 2016-07-20 MX MX2021013665A patent/MX2021013665A/es unknown
- 2016-07-20 IL IL246864A patent/IL246864B/en active IP Right Grant
- 2016-08-02 ZA ZA201605342A patent/ZA201605342B/en unknown
-
2018
- 2018-12-12 IL IL263669A patent/IL263669B/en active IP Right Grant
-
2019
- 2019-09-12 JP JP2019166361A patent/JP7164502B2/ja active Active
-
2020
- 2020-07-28 ZA ZA2020/04653A patent/ZA202004653B/en unknown
- 2020-09-02 US US17/010,354 patent/US20210087293A1/en active Pending
- 2020-09-28 AU AU2020244370A patent/AU2020244370B2/en active Active
- 2020-10-14 IL IL278062A patent/IL278062B/en unknown
-
2022
- 2022-10-20 JP JP2022168140A patent/JP2023015087A/ja active Pending
-
2024
- 2024-05-23 AU AU2024203436A patent/AU2024203436A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL278062B (en) | Plasma kallikrein-binding proteins and their uses in the treatment of hereditary angioedema | |
HK1252937A1 (zh) | 用於治療抑鬱症的方法和試劑盒 | |
IL259570A (en) | Combined therapy and their uses and methods | |
ZA201802854B (en) | Authentication methods and sysyems | |
IL261140A (en) | Antibodies against tnf-alpha and functional fragments thereof | |
EP3209298A4 (en) | Compositions and methods for treating insomnia | |
IL259691A (en) | Plasma kallikrein inhibitors and their uses for the treatment of hereditary angioedema attack | |
ZA202108600B (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
IL259096A (en) | Peptides and methods of treating endometriosis using the same | |
IL261261A (en) | Antibodies against tnf-alpha and functional fragments thereof | |
ZA201708223B (en) | Endostatin fragments and variants for use in treating fibrosis | |
IL261098A (en) | Antibodies against tnf-alpha and functional fragments thereof | |
EP3220908A4 (en) | Compositions and methods for treating endometriosis | |
IL261793A (en) | Anti-tnfalpha antibodies and their functional parts | |
EP3380468B8 (en) | Bis-pyridazine compounds and their use in treating cancer | |
EP3110453A4 (en) | Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions | |
IL257407A (en) | Compositions and methods for treating wounds | |
HUE046688T2 (hu) | Biztonsági hordozókban végrehajtott javítások | |
EP3270919A4 (en) | Compositions and methods for treating hepatocellular carcinoma | |
GB201418526D0 (en) | Kit and method for preventing or treating menopausal symptoms |